Both anthracyclines and topoisomerase II inhibitors are used in the treatment of AML [3,5], but it is not known whether Exportin 1 inhibitors can be used to overcome conventional drug resistance in human AML cells. Here, XPO1 is linked to acute myeloid leukemia.